Smith Jodi M, Nemeth Thomas Lajos, McDonald Ruth A
Division of Nephrology, Children's Hospital and Regional Medical Center, 4800 Sand Point Way, NE 5G-1, Seattle, WA 98105-0371, USA.
Pediatr Clin North Am. 2003 Dec;50(6):1283-300. doi: 10.1016/s0031-3955(03)00121-4.
Advances in immunosuppressive therapy over the past decade have led to dramatic improvements in graft survival. With the development of new agents, the focus of the transplant community is to establish regimens that maintain excellent graft survival rates but with fewer toxicities including infection, nephrotoxicity, malignancy, and cosmetic effects. Examples include the use of steroid-free protocols and calcineurin avoidance regimens, which are currently being studied by NAPRTCS. The ultimate goal of transplant immunosuppressive therapy is the induction of tolerance. As we learn more about immune function from basic and clinical research, tolerance to allografts seems a more reachable goal.
在过去十年中，免疫抑制疗法的进展使移植物存活率得到了显著提高。随着新型药物的开发，移植领域的重点是建立既能保持优异的移植物存活率，又能减少包括感染、肾毒性、恶性肿瘤和美容影响等毒性的治疗方案。例如使用无类固醇方案和避免使用钙调神经磷酸酶的方案，目前北美儿科肾脏移植协作研究组织（NAPRTCS）正在对其进行研究。移植免疫抑制治疗的最终目标是诱导免疫耐受。随着我们从基础和临床研究中对免疫功能了解得更多，对同种异体移植物的耐受似乎是一个更可实现的目标。
